Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T06421
|
||||
Former ID |
TTDS00492
|
||||
Target Name |
Interferon-alpha/beta receptor
|
||||
Gene Name |
IFNAR2
|
||||
Synonyms |
IFN-R; IFN-alpha-REC; Interferon alpha/beta receptor; Type I interferon receptor; IFNAR2
|
||||
Target Type |
Successful
|
||||
Disease | Advanced renal cell carcinoma [ICD9: 189; ICD10: C64] | ||||
Endometriosis [ICD9: 617; ICD10: N80] | |||||
Hairy cell leukemia, malignant melanoma; Chronic myelogenous leukaemia [ICD9:172, 202.4, 208.9, 205.1; ICD10: C43, C91-C95, C91.4, C92.1] | |||||
Hairy cell leukemia; HCV infection [ICD9:202.4, 070.4, 070.5, 070.70; ICD10: C91.4, B17.1, B18.2] | |||||
Hairy cell leukemia [ICD9: 202.4; ICD10: C91.4] | |||||
Multiple scierosis [ICD9: 340; ICD10: G35] | |||||
Systemic lupus erythematosus; Myositis [ICD9: 695, 710.0, 729.1; ICD10: L51-L54, M32, M60] | |||||
Function |
Receptor forinterferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the tyr kinase, jak1. Isoform 1 also interacts with the transcriptional factors, stat1 and stat2. Both forms are potent inhibitors of type i ifn activity.
|
||||
BioChemical Class |
Type II cytokine receptor
|
||||
UniProt ID | |||||
Sequence |
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR |
||||
Drugs and Mode of Action | |||||
Drug(s) | Interferon Alfa-2b, Recombinant | Drug Info | Approved | Hairy cell leukemia | [536361] |
Interferon alfa-n1 | Drug Info | Approved | Hairy cell leukemia, malignant melanoma; Chronic myelogenous leukaemia | [536361], [551871] | |
Interferon alfacon-1 | Drug Info | Approved | Hairy cell leukemia; HCV infection | [536361], [551871] | |
Interferon beta-1b | Drug Info | Approved | Multiple scierosis | [536361] | |
Sifalimumab | Drug Info | Approved | Advanced renal cell carcinoma | [529282], [543015] | |
Sifalimumab | Drug Info | Phase 2 | Systemic lupus erythematosus; Myositis | [543015], [551134] | |
Alfa-interferon | Drug Info | Phase 1 | Endometriosis | [530984] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
PI3K-Akt signaling pathway | |||||
Osteoclast differentiation | |||||
Toll-like receptor signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Natural killer cell mediated cytotoxicity | |||||
Hepatitis C | |||||
Hepatitis B | |||||
Measles | |||||
Influenza A | |||||
Herpes simplex infection | |||||
Reactome | Interferon alpha/beta signaling | ||||
Regulation of IFNA signaling | |||||
WikiPathways | Toll-like receptor signaling pathway | ||||
Interferon type I signaling pathways | |||||
Interferon alpha/beta signaling | |||||
Regulation of toll-like receptor signaling pathway | |||||
Osteoclast Signaling | |||||
References | |||||
Ref 530984 | A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Med Pediatr Oncol. 1991;19(4):276-82. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 535821 | The clinical application of the interferons: a review. NSW Therapeutic Assessment Group. Med J Aust. 1992 Jun 15;156(12):869-72. | ||||
Ref 536772 | New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. | ||||
Ref 537155 | Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46. | ||||
Ref 537218 | Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoietic stem cell transplantation with donor lymphocyte transfusion and interferon-alpha-2b. Leuk Res. 2009 Aug;33(8):e111-3. Epub 2009 Apr 10. | ||||
Ref 537596 | Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170. | ||||
Ref 538052 | Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology. 1997 Sep;26(3 Suppl 1):96S-100S. | ||||
Ref 538094 | Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.